Acrivon Therapeutics
ACRV
44 hedge funds and large institutions have $22.6M invested in Acrivon Therapeutics in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 13 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
8% less funds holding
Funds holding: 48 → 44 (-4)
17.07% less ownership
Funds ownership: 58.98% → 41.91% (-17%)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
50% less capital invested
Capital invested by funds: $44.9M → $22.6M (-$22.3M)
Top Buyers
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3.96M |
| 2 |
ACA
Acorn Capital Advisors
New York
|
-$977K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$548K |
| 4 |
Two Sigma Investments
New York
|
-$341K |
| 5 |
Millennium Management
New York
|
-$293K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
51
Schonfeld Strategic Advisors
New York
| – | -$39.6K | -16,428 | Closed |
|
52
Citigroup
New York
| – | -$35.2K | -14,592 | Closed |
|
53
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$30K | -12,433 | Closed |
|
54
Point72 Asset Management
Stamford,
Connecticut
| – | -$26.2K | -10,876 | Closed |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2.94K | -1,686 | -99% |
|
|
EWA
56
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$899 | -373 | Closed |
|
|
OC
57
Optima Capital
Beaverton,
Oregon
| – | -$670 | -278 | Closed |
|
ACRV Hedge Fund Activity: Q1 2026 in Review
44 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q1 2026, worth a combined $22.6M — down 50% from $44.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ACRV and 10 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 11 added.
The largest buyer was Acadian Asset Management, adding an estimated $462K. The largest seller was Citadel Advisors, exiting entirely with an estimated $3.96M sold.
- 44 institutional investors held Acrivon Therapeutics (ACRV) as of Q1 2026, down from 48 in Q4 2025.
- Funds reported $22.6M of Acrivon Therapeutics stock for Q1 2026, down 50% quarter-over-quarter.
- 10 funds opened new Acrivon Therapeutics positions in Q1 2026 and 13 closed out, a net change of -3 holders.
- The largest Acrivon Therapeutics buyer in Q1 2026 was Acadian Asset Management, an estimated $462K added.
- The largest Acrivon Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $3.96M sold.
Based on aggregated 13F filings for Q1 2026.